Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		10786772
	Filing Date		2004-02-25
	First Named Inventor	Bunke	er, Ross et al.
	Art Unit		2167
	Examiner Name	Pham	, Michael
	Attenney Dealest Number		DEAC 04427UC4

				Attorn	ey Doc	ket Number	BEAS-01437US	1			
							-				
					U.S.I	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add		_
			U.S.P	ATENT	APPLIC	CATION PUBL	ICATIONS		Remove		_
Examiner Initial*	aminer Cite No Publication Number Kind Code ¹ Date Name of Patente of cited Document			Releva		Lines where ges or Relev					
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document	e or	vhere Rele	or Relevant	т.
	1	00/29924	wo			2000-05-25	Saga Software Inc				
	2	2248634	CA			2000-03-24	IBM Canada				С
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		_

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10786772
iling Date		2004-02-25
irst Named Inventor Bunke		er, Ross et al.
rt Unit		2167
xaminer Name Pham		, Michael
ttorney Docket Number		BEAS-01437US1

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	J5					
	1	ALLAMARAJU et al., "Professional Java Server Programming JZEE 1.3 Edition," September 2001, WROX, XP002442939 pp. 1009-1057						
	2	SLIN MICROSYSTEMS, INC., "JZEE Commerciar Architecture 1.0," August 2001, XP002442654, retrieved from the Internet: http://java.sun.com/jZee/commerciar/download html-, pp. 1-179						
	3	Supplementary European Search Report dated August 8, 2007, for European Patent Application No. EP 02784131.1, 4 pages						
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add	Ξ					
		EXAMINER SIGNATURE						
Examiner	Signa	sture Date Considered	_					

A

E

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at view (LISPTO, COD) or MPEP 901.04. 2 Enter office that issued the document, by the hor-left posted (WIPO) Standard 51.3.) 1 Fee Lispanese patent for counters, the indication of the parent for integrating or the Emperor may precede the settle more of the patent for which of the patent for integrating or the Emperor may precede the settle may be of the patent for integrating or the Emperor may precede the settle may be officed as a check mark here if English targuages threatistics in a standard.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10786772		
Filing Date		2004-02-25		
First Named Inventor	Bunke	lunker, Ross et al.		
Art Unit		2167		
Examiner Name	Pham	, Michael		
Attorney Docket Number		BEAS-01437US1		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Guanyao Cheng/	Date (YYYY-MM-DD)	2007-09-21
Name/Print	Guanyao Cheng	Registration Number	58 555

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.9 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary (Tifice, U.S. perpartment of Commence, P. 0. Box 1450, Alexandria, V.S.2311-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.